Press Releases
Sep 19, 2024
Couragene Receives NIH STTR Grant to Advance Non-viral Genome Editing Therapy for Angelman Syndrome
NORTH BRUNSWICK, NJ— Couragene, a pioneering biotechnology company focusing on next-generation genetic medicine, is proud to announce the receipt of a Small Business Technology Transfer (STTR) Phase I grant from the National Institutes of Health (NIH) to advance its work on Engineering Chemically Modified RNPs for Effective Treatment of Angelman Syndrome. This competitive award supports Couragene’s collaboration with Yale University to develop non-viral genome editing therapy for Angelman syndrome.
Learn more about the awarded NIH STTR project.
Feb 14, 2025
Couragene and FAST Launch CourageAS to Develop Genome Editing Therapies for Angelman Syndrome
NORTH BRUNSWICK, NJ— Couragene is proud to announce the launch of CourageAS Biotherapeutics, a joint venture with the Foundation for Angelman Syndrome Therapeutics (FAST) to advance an investigational non-viral delivered genome-editing program for Angelman Syndrome. CourageAS is dedicated to developing breakthrough genome editing therapies for Angelman syndrome. By combining Couragene’s cutting-edge non-viral delivery platform technologies with FAST’s deep patient advocacy, CourageAS aims to accelerate the path from discovery to transformative treatments for Angelman Syndrome.
Learn more about CourageAS.
Oct 10, 2023
Couragene Co-founders Developing Gene Editing Technology for Genetic Diseases Awarded Major Federal Grant
NORTH BRUNSWICK, NJ— Couragene, a genetic medicines company using novel delivery platforms, announces today that its co-founders Yong-Hui Jiang and Jiangbing Zhou of Yale University, together with Elizabeth Berry-Kravis of RUSH University have been awarded a competitive UG3/UH3 grant from the NIH’s Somatic Cell Genome Editing (SCGE) program. This monumental grant, totaling roughly $40 million contingent on milestones, marks a momentous step forward in leveraging genome editing to combat neurogenetic diseases.